Treatment Practices for Extended-Stage Small Cell Lung Cancer

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

The addition of angiogenesis inhibition to immunochemotherapy for untreated extensive-stage small cell lung cancer did not significantly increase toxicity.

Data from a phase 1 trial showed an ORR of 68% and a DCR of 93% with ZL-1310 in those with extensive-stage small cell lung cancer during dose escalation.